FDA Clearance Tracker · P930027
IMMULITE SYSTEMS PSA & THIRD GENERATION PSA REAGENTS
Last checked: Nov 20, 2026Latest source record: Sep 15, 1995 (this decision)Source: openFDAMethods & limitations
Decided
Sep 15, 1995
Approved
Time to decision
766 days
Received Aug 10, 1993. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA
Device class
Class III
The decision
- FDA number
- P930027
- Device name
- IMMULITE SYSTEMS PSA & THIRD GENERATION PSA REAGENTS
- Applicant
- Siemens Healthcare Diagnostics, Inc.
- Applicant location
- Gwynedd Ll55 4el
- Received
- Aug 10, 1993
- Decided
- Sep 15, 1995
- Decision
- Approved
Device type
- Device type
- Total, prostate specific antigen (noncomplexed & complexed) for detection of prostate cancer (MTF)
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
APPROVAL FOR THE COAT-A-COUNT PSA IRMA
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- We could not check whether this was the first decision under its product code.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
Other decisions for Siemens Healthcare Diagnostics, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K260674 · Decided Nov 6, 2026 · 249 days after receipt
Device type: System, Test, Vitamin D (MRG) · Laboratory Medicine & Pathology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.